At the 2024 European College of Neuropsychopharmacology (ECNP) Congress, researchers have presented work that could lead to ways to boost brain development and prevent neurodegeneration in individuals with Down syndrome.
At the 2024 European College of Neuropsychopharmacology (ECNP) Congress, researchers have presented work that could lead to ways to boost brain development and prevent neurodegeneration in individuals with Down syndrome.
Iama Therapeutics Srl has sought new, selective inhibitors of solute carrier family 12 member 2 (NKCC1) to treat autism, Down syndrome and brain disorders featuring chloride (NKCC1/solute carrier family 12 member 5 [KCC2]) imbalance.
Treatment with injections of gonadotropin-releasing hormone (GnRH), indicated to prevent sexual maturation deficits in Down syndrome, also reduced cognitive function impairment associated with Down syndrome, also called trisomy 21. With age, about three-quarters of people with Down syndrome develop Alzheimer's disease. They also lose their sense of smell. Both circumstances could improve with pulse doses of GnRH, according to a study led by the French National Institute of Health and Medical Research (Inserm) and the University of Lausanne (UNIL) published in the Sept. 1, 2022, issue of Science.
Treatment with injections of gonadotropin-releasing hormone, indicated to prevent sexual maturation deficits in Down syndrome, also reduced cognitive function impairment associated Down syndrome, also called trisomy 21.
Trisomy 21, the abnormal third copy of chromosome 21 causing developmental disorders in Down syndrome, has been shown to promote reorganization of the entire neural progenitor cell (NPC) genome, with the resulting gene transcription and cell function disruption being so similar to senescence that anti-senescence drugs could correct them in cell cultures.
